Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar

•Long-term safety of satralizumab in NMOSD was evaluated in SAkuraSky & SAkuraStar.•The safety profile of satralizumab was comparable between the DB and OST periods.•Rates of adverse events in the OST were comparable with the DB periods.•Overall, rates of infections and serious infections did no...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2022-10, Vol.66, p.104025-104025, Article 104025
Hauptverfasser:	Yamamura, Takashi, Weinshenker, Brian, Yeaman, Michael R., De Seze, Jerome, Patti, Francesco, Lobo, Patricia, von Büdingen, H.-Christian, Kou, Xiujing, Weber, Kristina, Greenberg, Benjamin
Format:	Artikel
Sprache:	eng
Schlagworte:	All clinical trials All demyelinating disease (CNS) Autoimmune diseases Devic's syndrome Neuromyelitis optica spectrum disorder Patient safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!